iQur Ltd is a specialist biotechnology company offering fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programmes.

iQur enables confident decision making in disease management and clinical research through products and services that are

• Fast - typical turnaround within five working days
• Flexible - providing bespoke solutions that best meet your needs
• Secure - accurate and reliable results delivered by our CPA-accredited laboratory
• Innovative - measuring liver fibrosis using serum markers (ELF^TM Test)

Customer satisfaction is paramount and iQur delivers the highest level of service to clients in a variety of healthcare related sectors, including

• the NHS
• community services
• private healthcare companies
• the pharmaceutical industry
• clinical research organisations
• academic research centres
• charities and patient support groups

By accommodating individual requirements efficiently and professionally, we enable clients to comply with national guidelines, fulfil research needs and, above all, provide the finest care for patients.

Our clients can be confident of receiving reliable, accurate results within the shortest possible time from our fully accredited centralised testing laboratory.

Data Protection Act (Reg. Z8042124). Company registration number 4665665 (Registered in England). VAT number: 825 677 790 HepCgen® and iQur® are internationally registered trademarks of our company.